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Background: Exploring variation in patients’ experiences of involvement in treatment decision making can identify groups
needing extra support, such as additional consultation time, when considering treatment options.
Methods: We analysed data from the 2010 English National Cancer Patient Experience Survey, a national survey of all patients
attending hospitals in England for cancer treatment over a 3-month period, to examine how experience of involvement in decisions
about treatment varied between patients with 38 different primary cancers using logistic regression. We analysed responses from
41411 patients to a single question examining patient experience of involvement in treatment decision making. We calculated
unadjusted odds ratios of reporting the most positive experience between patients of different sociodemographic and tumour
characteristics and explored the effects of adjusting for age, gender, ethnicity, deprivation, cancer type and hospital of treatment.
Results: Of the 41 441 respondents, 29 776 (72%) reported positive experiences of decision-making involvement. Younger patients
reported substantially less positive experiences of involvement in decision making (adjusted OR¼ 0.49 16–24 vs 65–74; Po0.001),
as did ethnic minorities (adjusted ORs¼ 0.52, 0.62 and 0.73 for Black, Chinese and Asian vsWhite patients, respectively; Po0.001).
Experience varied considerably between patients with different cancers ( e.g., OR¼ 0.52 for anal and 1.37 for melanoma vs colon
cancer; Po0.001), with ovarian, myeloma, bladder and rectal cancer patients reporting substantially worse experiences compared
with other patients with gynaecological, haematological, urological and colorectal cancers, respectively. Clustering of different
patient groups within hospitals with outlying performance report scores could not account for observed differences.
Conclusion: Efforts to improve involvement in treatment decision making can focus on those who report the worst experience, in
particular younger patients, ethnic minorities and patients with rectal, ovarian, multiple myeloma and bladder cancer.
Modern health-care systems rightly consider shared decision
making (i.e., effectively involving patients in decisions about their
treatment) to be an essential component of patient-centred care
(Committee On Quality Of Health Care In America, 2001;
Secretary of State for Health, 2010; Barry and Edgman-Levitan,
2012; Stiggelbout et al, 2012) and cancer care in particular (Epstein
and Street, 2007). More positive experiences of involvement in
cancer treatment decision making are associated with reduced
decisional conflict (i.e., patient-reported difficulty in making
decisions), greater satisfaction with treatment decisions and
*Correspondence: Dr A EI Turabi; E-mail: ae300@medschl.cam.ac.uk
Previous presentations of related work: El Turabi, A: Variations in satisfaction with involvement in decisions about cancer treatment: analysis of the
National Cancer Patient Experience Survey 2010. Presented at the National Cancer Intelligence Network Cancer Outcomes Conference,
Birmingham, UK, June 14–15, 2012.
Received 19 February 2013; revised 26 May 2013; accepted 3 June 2013;
published online 27 June 2013
& 2013 Cancer Research UK. All rights reserved 0007 – 0920/13
FULL PAPER
Keywords: decision making; patient experience; surveys; health inequalities; ethnicity; age
British Journal of Cancer (2013) 109, 780–787 | doi: 10.1038/bjc.2013.316
780 www.bjcancer.com |DOI:10.1038/bjc.2013.316
improved patient well-being (Gattellari et al, 2001; Keating et al,
2002; Brown et al, 2012). Although patients with different
sociodemographic characteristics tend to report variable experi-
ences of care (Campbell et al, 2001; Weech-Maldonado et al, 2003;
Goldstein et al, 2009; Mead and Roland, 2009; Elliott et al, 2010;
Lyratzopoulos et al, 2012a), relatively little is known about how the
experience of shared decision making varies between patients with
cancers (Hubbard et al, 2008). Understanding such variation can
help identify patient groups who may require additional time and
support in making decisions about their treatment (Friedberg et al,
2013).
Previous studies have used patient survey data to describe and
explore possible reasons for sociodemographic disparities in
patient experience of primary and hospital care (Rodriguez et al,
2009; Elliott et al, 2010; Lyratzopoulos et al, 2012a). Until recently,
however, few large national surveys of sufficient quality had been
conducted to enable a robust analysis of the experiences of cancer
patients, and previous relevant evidence is constrained in relation
to sample size and number of studied cancers (Hubbard et al, 2008;
Ayanian et al, 2010).
The English National Health Service Cancer Patient Experience
Survey 2010 is one of the largest surveys of cancer patient
experience ever undertaken (Box 1) (Department of Health,
2010a). Using data from this survey, we sought to examine
whether patient experience of involvement in treatment decision
making varied between patients of different age, gender, ethnicity,
socioeconomic deprivation and cancer diagnosis. We also sought
to establish whether any observed differences might be accounted
for by clustering of patient groups reporting less positive
experiences in poorly performing hospitals.
MATERIALS AND METHODS
Participants and data. We analysed data from the 2010 National
Cancer Patient Experience Survey (NCPES) (Department of
Health, 2010b). These included data on patients’ responses to
survey questions, sociodemographic characteristics and primary
cancer diagnosis. All patients received the survey in the first half of
2010 having attended hospital for management of their cancer
between January and March of the same year, although answers
given may refer to a different period. The majority of analysed
respondents (66%) indicated that they were diagnosed in the last
year. We used respondent-reported information on patients’
gender, age and ethnicity (2001 Census Office for National
Statistics (ONS) ethnicity classification). Data on patient area
deprivation (Index of Multiple Deprivation 2007 score of patients’
lower super output area of residence) (Noble et al, 2007) and
cancer diagnosis were derived by the survey provider from hospital
administrative records. Cancer diagnoses were defined according
to the International Classification of Diseases 10 codes
(Supplementary Appendix 1). We categorised respondents into
eight age groups and six ethnic groups based on ONS classification
(Supplementary Appendix 2), and defined patients’ national
(England) deprivation quintiles (quintile-defining points: 8.257,
13.525, 20.741 and 33.511).
We analysed responses to the single NCPES question evaluating
the experience of involvement in decisions about treatment: ‘Were
you as involved in decisions about which treatment you would have
as you wanted?’ Respondents with a diagnosis of a known primary
cancer were included in our analysis if they provided an
informative response to this question and had completely observed
data on all sociodemographic variables.
Statistical analysis. Measures of patient experience included in
NCPES are reported publicly, both for England as a whole and
also by each hospital, and fed back to health service managers
and clinical teams using binary categorisations for more or
less positive patient experience (Department of Health, 2010a;
Quality Health, 2010b). In such reports the measure of patient
experience of involvement in decision making about treatment
compares the most positive responses to the question (‘Yes,
definitely’) with less positive responses (‘Yes, to some extent’,
‘No, but I would like to have been more involved’). Unin-
formative responses (‘Only one type of treatment was suitable for
me’) are excluded. Accordingly, we used this binary outcome to
explore variation in experience of involvement in treatment
decision making between different patient groups. We also
examined alternative binary definitions of this item in sensitivity
analysis.
We described the proportion of patients in each sociodemo-
graphic group and cancer type who reported the most positive
experience of involvement in treatment decision making and
calculated respective unadjusted odds ratios using logistic regres-
sion (model 1). To examine whether any observed variation was
because of confounding by patient factors, we then adjusted for all
observed sociodemographic variables and cancer type using a
multivariable fixed-effects logistic regression model (model 2).
Then, to examine whether any variation was explained by
clustering of patients from certain groups in hospitals with lower
or higher than average performance, we constructed a mixed-
effects model, augmenting model 2 with a random effect
(intercept) for hospital of treatment (model 3).
Using post hoc comparisons derived from model 3, we examined
how reported experience of involvement in treatment decision
making varied between cancers treated by the same cancer
specialty teams. This within-specialty variation may provide
further insights about the potential sources of observed variation.
After adjusting for patient characteristics, variations between
cancers treated by the same specialty teams are more plausibly
explained by differences in disease factors, such as diagnostic and
treatment pathways, severity of illness and prognosis, than
differences in the way that health-care professionals might involve
patients in decision making.
Box 1 The Cancer Patient Experience Survey-key facts.
The 2010 English National Health Service Cancer Patient Experience Survey
(NCPES) is one of the largest surveys of experience of cancer patients in any
country.
 Conducted on behalf of the English Department of Health with
the aims of monitoring national progress in cancer care and
driving quality improvements locally.
 Sent to all adult patients with a primary diagnosis of cancer who
were treated in a hospital as inpatient or day-case patients in the
first quarter of 2010.
 Excluded non-NHS (private) patients, patients not resident in the
United Kingdom and patients who had died before surveys were
distributed.
 Postal survey with two reminders for nonrespondents.
 Sent to 101 773 unique patients; 67 713 responded (67% response
rate).
 Contained 59 evaluative questions covering 15 aspects of
patients’ experiences of care.
 Four rounds of cognitive testing undertaken to improve the
comprehensibility, acceptability and reliability of question items
(Quality Health, 2010a).
 Results reported nationally and for each hospital and by 13 major
cancer groups (Department of Health, 2010a; Quality Health,
2010b).
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Table 1. Patient experience of involvement in decision making about treatment
Unadjusted odds of reporting
most positive experience of
shared decision making
(model 1)
Odds adjusted for
patient characteristicsa
(model 2)
Odds adjusted for patient
characteristics and hospitalb
(model 3)
%
Reporting
most
positive
experience
Odds
ratio 95% CI P-value*
Odds
ratio 95% CI P-value*
Odds
ratio 95% CI P-value*
Gender
Male (n¼ 19566) 72.0 Ref Ref Ref
Female (n¼ 21875) 71.7 0.98 (0.94–1.03) 0.463 0.97 (0.91–1.02) 0.249 0.97 (0.91–1.03) 0.258
Age
16–24 (n¼ 233) 59.1 0.48 (0.37–0.63) 0.49 (0.37–0.64) 0.49 (0.37–0.65)
25–34 (n¼ 634) 64.7 0.61 (0.52–0.72) 0.59 (0.49–0.70) 0.59 (0.49–0.70)
35–44 (n¼ 2099) 63.9 0.59 (0.53–0.65) 0.56 (0.51–0.62) 0.56 (0.50–0.62)
45–54 (n¼ 5676) 66.4 0.66 (0.62–0.70) o0.001 0.63 (0.59–0.68) o0.001 0.63 (0.58–0.67) o0.001
55–64 (n¼ 10744) 73.0 0.90 (0.85–0.95) 0.88 (0.83–0.94) 0.88 (0.83–0.94)
65–74 (n¼ 13028) 75.0 Ref Ref Ref
75–84 (n¼ 7533) 72.6 0.88 (0.83–0.94) 0.90 (0.84–0.96) 0.90 (0.84–0.96)
85þ (n¼ 1494) 69.7 0.77 (0.68–0.86) 0.79 (0.70–0.88) 0.79 (0.70–0.89)
Ethnicity
White (n¼ 39809) 72.3 Ref Ref Ref
Mixed (n¼ 180) 62.2 0.63 (0.47–0.85) 0.73 (0.54–1.00) 0.73 (0.53–0.99)
South Asianc (n¼ 696) 63.5 0.67 (0.57–0.78) 0.73 (0.62–0.86) 0.75 (0.64–0.88)
Black (n¼ 607) 55.5 0.48 (0.41–0.56) o0.001 0.52 (0.44–0.62) o0.001 0.54 (0.45–0.64) o0.001
Chinese (n¼97) 59.8 0.57 (0.38–0.85) 0.62 (0.41–0.94) 0.63 (0.42–0.95)
Other (n¼ 52) 59.6 0.56 (0.32–0.98) 0.64 (0.36–1.11) 0.66 (0.38–1.16)
Socioeconomic deprivation
Least deprived (n¼ 9396) 72.8 Ref Ref Ref
2nd quintile (n¼ 9430) 73.0 1.01 (0.95–1.08) 1.01 (0.95–1.08) 1.01 (0.95–1.08)
3rd quintile (n¼ 8772) 71.2 0.92 (0.87–0.99) o0.001 0.93 (0.87–0.99) o0.001 0.93 (0.87–0.99) o0.046
4th quintile (n¼7525) 71.6 0.94 (0.88–1.01) 0.98 (0.92–1.05) 0.98 (0.91–1.05)
Most deprived (n¼ 6318) 70.0 0.87 (0.81–0.94) 0.94 (0.88–1.01) 0.94 (0.87–1.01)
Cancer type
Breast
Breast (n¼ 10366) 72.3 0.81 (0.73–0.88) o0.001 0.94 (0.85–1.04) o0.001 0.94 (0.85–1.04) o0.001
CNS
Brain (n¼ 300) 69.7 0.71 (0.55–0.92) 0.88 (0.67–1.14) 0.85 (0.65–1.10)
Other CNS (n¼ 85) 72.9 0.83 (0.51–1.35) o0.001 0.96 (0.59–1.56) o0.001 0.96 (0.58–1.57) o0.001
Colorectal
Colon (n¼ 3225) 76.5 Ref Ref Ref
Rectal (n¼ 2290) 70.2 0.73 (0.64–0.82) 0.73 (0.65–0.82) 0.73 (0.65–0.82)
Anal (n¼ 145) 61.3 0.49 (0.35–0.69) o0.001 0.52 (0.37–0.74) 0.52 (0.37–0.74)
Other colorectal (n¼139) 69.8 0.71 (0.49–1.03) 0.73 (0.50–1.06) 0.74 (0.51–1.07)
Gynaecological
Ovarian (n¼ 1165) 70.1 0.72 (0.62–0.84) 0.77 (0.66–0.90) 0.77 (0.66–0.89)
Uterine (n¼ 798) 79.0 1.15 (0.96–1.39) 1.20 (0.99–1.45) 1.18 (0.97–1.43)
Cervical (n¼ 266) 65.4 0.58 (0.45–0.76) 0.79 (0.60–1.03) o0.001 0.76 (0.58–1.01) o0.001
Vulvo-vaginal (n¼ 147) 78.2 1.11 (0.74–1.65) 1.19 (0.79–1.78) 1.16 (0.77–1.73)
Other gynaecological
(n¼ 38)
73.7 0.86 (0.42-1.78) 1.00 (0.48–2.09) 0.99 (0.47–2.06)
Haematological
Non-Hodgkin’s lymphoma
(n¼ 2381)
69.2 0.69 (0.61–0.78) 0.72 (0.64–0.81) 0.72 (0.64–0.81)
Myeloma (n¼ 1873) 66.3 0.61 (0.53–0.69) 0.61 (0.54–0.70) 0.61 (0.54–0.69)
Leukaemia (n¼ 1650) 72.4 0.81 (0.71–0.93) o0.001 0.89 (0.77–1.02) o0.001 0.88 (0.77–1.01) o0.001
Hodgkin’s disease (n¼ 320) 62.8 0.52 (0.41–0.66) 0.73 (0.57–0.94) 0.74 (0.57–0.95)
Other haematological
(n¼ 88)
71.6 0.78 (0.48–1.24) 0.88 (0.55–1.41) 0.87 (0.54–1.40)
Head and neck
Other head and neck
(n¼ 804)
71.3 0.76 (0.64–0.91) 0.82 (0.69–0.98) 0.80 (0.67–0.96)
Thyroid (n¼ 289) 68.5 0.67 (0.52–0.87) o0.001 0.87 (0.66–1.13) o0.001 0.84 (0.65–1.10) o0.001
Laryngeal (n¼ 242) 74.0 0.87 (0.65–1.18) 0.87 (0.64–1.17) 0.85 (0.63–1.14)
Lung
Lung (n¼ 2193) 72.0 0.79 (0.70–0.90) 0.78 (0.69–0.88) 0.77 (0.68–0.87)
Mesothelioma (n¼ 231) 77.1 1.03 (0.75–1.42) o0.001 0.98 (0.71–1.35) o0.001 0.97 (0.70–1.33) o0.001
Other thoracic (n¼ 34) 67.7 0.64 (0.31–1.33) 0.72 (0.35–1.50) 0.70 (0.34–1.46)
Other
Other (n¼ 244) 65.6 0.59 (0.44–0.77) o0.001 0.62 (0.47–0.82) o0.001 0.61 (0.46–0.80) o0.001
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Finally, to assess potential bias that could have resulted by
differential perception that ‘only one treatment was suitable’
between different patient groups, we compared the characteristics
of respondents who were included and excluded from the analysis.
We also performed two extreme case scenario sensitivity analyses
whereby all excluded respondents were assumed to have provided
informative responses, either all indicating a positive experience or
all indicting a negative experience.
Significance was tested with joint Wald tests for categorical
variables. All analyses were performed using Stata v12.0 (StataCorp,
College Station, TX, USA).
RESULTS
A total of 101 773 patients were invited to complete the survey and
67 713 (67%) responded. Of these, 64 201 responded to the
question regarding experience of involvement in decisions about
treatment, of whom 48 396 provided informative responses.
Analysis was restricted to 41 441 of these patients with a primary
tumour diagnosis and complete sociodemographic data
(Supplementary Appendix 3 and Supplementary Figure 1). Of
these respondents, 29 776 (72%) reported the most positive
experience of involvement in treatment decision making, 9197
(22%) reported conditionally positive experience and 2468 (6%)
reported definitely negative experience.
In unadjusted analysis of different patient groups (model 1),
there was very strong evidence of variation in experience of
involvement in decision making about treatment between patients
with different cancer types (Po0.001; Table 1). Among the group
of most common cancers, patients with melanoma were substan-
tially more likely to report the most positive experience than
patients with other cancers (unadjusted OR melanoma vs colon
1.28; Po0.001), whereas patients with anal cancers and myeloma
reported the most negative experience (unadjusted OR vs colon
0.49 and 0.61, respectively; Po0.001). There was no evidence of
Table 1. ( Continued )
Unadjusted odds of reporting
most positive experience of
shared decision making
(model 1)
Odds adjusted for
patient characteristicsa
(model 2)
Odds adjusted for patient
characteristics and hospitalb
(model 3)
%
Reporting
most
positive
experience
Odds
ratio 95% CI P-value*
Odds
ratio 95% CI P-value*
Odds
ratio 95% CI P-value*
Sarcoma
Soft-tissue sarcoma
(n¼ 296)
70.7 0.74 (0.57–0.96) 0.79 (0.61–1.03) 0.77 (0.59–1.00)
Bone sarcoma (n¼ 99) 68.7 0.68 (0.44–1.04) o0.001 0.85 (0.55–1.32) o0.001 0.83 (0.53–1.30) o0.001
Kaposi’s sarcoma (n¼ 11) 54.6 0.37 (0.11–1.21) 0.51 (0.15–1.72) 0.51 (0.15–1.71)
Skin
Melanoma (n¼687) 80.6 1.28 (1.04–1.58) o0.001 1.37 (1.11–1.69) o0.001 1.34 (1.08–1.65) o0.001
Upper GI
Oesophageal (n¼932) 72.3 0.80 (0.68–0.95) 0.79 (0.67–0.94) 0.79 (0.67–0.93)
Gastric (n¼664) 70.3 0.73 (0.61–0.88) 0.74 (0.61–0.89) 0.72 (0.60–0.87)
Pancreatic (n¼ 405) 71.1 0.76 (0.60–0.95) o0.001 0.76 (0.60–0.95) o0.001 0.74 (0.59–0.94) o0.001
Hepato-biliary (n¼ 247) 70.0 0.72 (0.54–0.96) 0.77 (0.57–1.02) 0.74 (0.55–0.99)
Other biliary (n¼ 83) 67.5 0.64 (0.40–1.02) 0.63 (0.39–1.01) 0.62 (0.39–0.99)
Urological
Prostate (n¼ 3882) 74.1 0.88 (0.79–0.98) 0.84 (0.75–0.94) 0.83 (0.74–0.93)
Bladder (n¼ 3868) 68.7 0.68 (0.61–0.75) 0.66 (0.59–0.73) 0.65 (0.58–0.72)
Renal (n¼ 528) 75.2 0.93 (0.75–1.15) o0.001 0.96 (0.77–1.19) o0.001 0.94 (0.76–1.17) o0.001
Testicular (n¼ 228) 74.1 0.88 (0.65–1.20) 1.28 (0.93–1.75) 1.27 (0.92–1.75)
Other urological (n¼ 198) 74.8 0.91 (0.65–1.27) 0.90 (0.65–1.26) 0.90 (0.64–1.25)
Abbreviations: CI¼ confidence interval; CNS¼ central nervous system; GI¼gastrointestinal; Ref¼ reference category. The odds ratios (ORs) of reporting an experience of involvement in
treatment decision making as positive as the reference group (‘Ref’) for each category of patients. An OR41 for a category shows that patients of that category are more likely to report positive
experience than the reference group; an ORo1 shows patients of that category are less likely to report positive experience than the reference group.
aMultivariable analysis, adjusting for cancer type and patient characteristics.
bMultivariable analysis, adjusting for cancer type and patient characteristics with a random-effect adjustment for hospital of treatment.
c‘South Asian’ ethnic group corresponds to the UK 2001 Census Office for National Statistics ethnicity classification group of ‘Asian or Asian British’, which includes patients describing
themselves as Indian, Pakistani, Bangladeshi or of ‘any other Asian background’. This classification system contains a distinct group for Chinese ethnicity.
*joint Wald tests of categorical variables.
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Figure 1. Adjusted odds ratios (with 95% confidence intervals) of
reporting experience of involvement in decision making about
treatment as positive as reference category for patients of different
cancer types (n¼ 41441). Results adjusted for gender, age, ethnicity,
socioeconomic deprivation, cancer type and a random effect for
treating hospital (model 3). Ref¼ reference category. The odds ratio
41 suggests category more likely to report positive experience than
reference category.
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differences in reported experience between sexes (unadjusted
OR women vs men 0.98; P¼ 0.463). Between different age
groups there was strong evidence of substantial variation
(Po0.001); patients in the 65–74 age group reported the most
positive experience, whereas younger patients reported substan-
tially less positive experience (unadjusted OR 16–24 vs 65–74 0.48),
as did patients older than the 65–74 age group (unadjusted OR
85þ vs 65–74 0.77). There was strong evidence that patients from
ethnic minorities were more likely to report a negative experience
than White patients (unadjusted OR vs White: Black 0.48, Chinese
0.57, South Asian 0.67; Po0.001). Experience also varied between
patients of differing socioeconomic backgrounds (Po0.001), but
the magnitude of this variation was small (unadjusted OR most
deprived vs least deprived 0.87).
Adjusting for all sociodemographic variables and cancer
diagnosis produced highly similar findings for cancer, age, sex
and ethnic variation (model 2), but variation by deprivation was
attenuated such that there was only weak evidence of variation
(P¼ 0.053). None of the above findings changed substantially
when hospital of treatment was included as a random effect (model
3 – see Table 1 and Figure 1), suggesting that the observed
variation was unlikely the result of clustering of certain patient
groups into hospitals with higher or lower performance. There
were only small differences in the demographic characteristics of
cases who were excluded from the analysis (e.g., because they
answered that only one treatment was suitable for them)
(Supplementary Appendix 3 and Supplementary Figure 2).
Furthermore, extreme case scenario sensitivity analyses about the
potential impact of differential perception or recall of shared
decision making produced similar findings for demographic
variables to those observed in the main analysis (Supplementary
Appendix 3 and Supplementary Table 1). Sensitivity analysis using
alternative dichotomisation of our response variable produced
broadly concordant findings (Supplementary Appendix 4).
Reported experience varied considerably between cancers
treated by the same teams of specialists (estimates derived from
model 3; Table 2). For example, patients treated for leukaemia
reported substantially more positive experience of involvement in
treatment decision making than patients with myeloma (adjusted
OR¼ 1.44 leukaemia vs myeloma; Po0.001). Similar patterns of
within-specialty variation were observed for colorectal, gynaeco-
logical and urological cancers, with patients with rectal, ovarian
and bladder cancer reporting notably worse experience than
patients with colon, uterine and renal cancers, respectively. There
was no such variation for upper gastrointestinal cancers.
DISCUSSION
Our findings indicate that within the context of a national health
service providing universal coverage, notable variations exist in
experience of involvement in decision making about cancer
treatment between patients with different cancers and of different
ages and ethnicities. Large variations also exist in the experience of
decision-making involvement between patients suffering from
cancers of the same system treated within the same specialty
service, for example, between patients with different gynaeco-
logical, haematological and urological cancers. These variations
could not be explained by concentration of patients reporting more
negative experiences in certain hospitals.
We know of no other national cancer patient survey including
patients with such a broad range of cancers. The large number of
participants allows us to examine relatively small patient groups,
overcoming the limitations of previous smaller studies (Hubbard
et al, 2008). The fact that the survey samples all patients nationally
strengthens the generalisability of our findings. Significant
limitations nevertheless exist in the use of patient survey data for
any substantive inquiry into health service quality, including the
lack of direct observation of patient care episodes and the effects of
potential for nonresponse bias (including survivorship, participa-
tion and recall biases) (Lyratzopoulos et al, 2012b). Our study
excluded respondents with missing sociodemographic data, those
without a recorded primary cancer diagnosis and those who
provided uninformative responses to the profiled question on
shared decision making. However, comparison of the character-
istics of respondents included and excluded from our analysis
indicated little difference between these groups (Supplementary
Appendix 3 and Supplementary Figure 2), suggesting limited
potential for any bias that can result from such exclusions. Also,
our data did not include variables on patients’ native language or
disease severity measures such as tumour stage or functional status,
potentially important variables in understanding observed ethnic
and tumour variation, respectively.
One limitation of the survey item analysed was the asymmetrical
response options offered to respondents. Although respondents
could indicate that they were insufficiently involved in decisions
Table 2. Within-specialty variation of patient experience of involvement
in decision making about treatment
Adjusted odds ratioa (higher
values indicate more likely to
report positive experience
of shared decision making) 95% CI
Colorectal cancers
Colon Ref
Rectal 0.73 (0.65–0.82)
Anal 0.52 (0.37–0.74)
Upper gastrointestinal cancers
Oesophageal Ref
Gastric 0.91 (0.73–1.14)
Pancreatic 0.95 (0.73–1.23)
Urological cancers
Bladder Ref
Prostate 1.28 (1.16–1.42)
Renal 1.46 (1.18–1.80)
Testicular 1.96 (1.43–2.69)
Gynaecological cancers
Ovarian Ref
Cervical 1.00 (0.75–1.33)
Vulvo-vaginal 1.51 (1.00–2.29)
Uterine 1.54 (1.25–1.91)
Haematological cancers
Myeloma Ref
Non-Hodgkin’s
lymphoma
1.18 (1.03–1.34)
Hodgkin’s disease 1.21 (0.93–1.56)
Leukaemia 1.44 (1.24–1.67)
Abbreviations: CI¼ confidence interval; Ref¼ reference category. The odds ratios (ORs) of
reporting an experience of involvement in treatment decision making as positive as the
reference group (‘Ref’) for each category of patients. An OR 41 for a category shows that
patients of that category are more likely to report positive experience than the reference
group; an OR o1 shows patients of that category are less likely to report positive
experience than the reference group.
aMultivariable analysis, adjusting for cancer type and patient age, gender, ethnicity,
socioeconomic deprivation and cancer diagnosis with a random effect adjustment for
hospital of treatment (derived from model 3).
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about treatment, there was no option for respondents to highlight
dissatisfaction with over-involvement in treatment decision
making. This may be an important omission given that previous
studies examining patient preference for involvement in treatment
decision making suggests a significant minority of patients prefer
to adopt a passive role in treatment decision making and that
involving these patients against their preference can provoke
anxiety (Hack et al, 1994; Hubbard et al, 2008). It may be useful to
develop survey questions that encompass a fuller spectrum of
patient preferences for shared decision making in the future.
Another limitation of our study is that we are not able to assess
whether doctors did indeed present all respondents with appro-
priate choice of treatment where such a choice was clinically
appropriate (the consultation style of some treating clinicians may
involve little shared decision making with the patient). We do
however judge the potential for bias arising from such a source to
be limited – particularly when considering differences between
cancers treated by doctors of the same clinical specialty and
multidisciplinary team. Furthermore, it was not possible to assess
the extent to which the patients’ perceptions concord with
objective measures of involvement in treatment decision making.
In principle, patients with certain characteristics may system-
atically perceive that only one type of treatment was suitable for
them more or less often than patients with other characteristics,
and this may result in bias. However, sensitivity analyses of the
potential impact of excluding patients with uninformative
responses provided similar findings to those observed in the main
analysis.
Variation in reported experience of involvement in decision
making between patients treated for different cancers may reflect
differences in disease factors. Patients with melanoma and
testicular cancer who reported the most positive experiences of
decision-making involvement are also generally diagnosed
promptly after symptomatic presentation and have relatively good
prognoses (5-year relative survival 480%) (Coleman et al, 2004;
Lyratzopoulos et al, 2012b). In contrast, patients with multiple
myeloma who reported nearly the worst experience of decision-
making involvement are likely to experience a delayed diagnosis,
and have a relatively poor prognosis (5-year relative survival
o30%) (Coleman et al, 2004; Lyratzopoulos et al, 2012b). There
was also substantial variation in experience of decision-making
involvement between patients with cancers treated by the same
specialty but which present different diagnostic or treatment
challenges or have variable functional outcomes and prognosis. For
example, patients with colon cancer reported substantially more
positive experiences of involvement in decision making than patients
with rectal cancer. Although colon and rectal cancer share similar
presentations and diagnostic pathways, they differ substantially with
respect to treatment patterns and functional outcomes: in contrast
with colon cancer patients, approximately two-thirds of patients
with rectal cancer treated by surgery require stoma formation, which
is permanent in at least a quarter of all patients (Finan et al, 2010).
Greater evidential uncertainty about optimal treatment of some
cancers such as prostate cancer, or greater intensity or complexity of
treatment and surveillance protocols such as for non-Hodgkin’s
lymphoma, may create greater decisional conflict for patients and a
less positive experience.
Patients with cancer who wereo55 years old reported the most
negative experience of involvement in treatment decision making;
a finding consistent with evidence from many other patient surveys
(Weech-Maldonado et al, 2003; Hubbard et al, 2008; Lyratzopoulos
et al, 2012a). Young patients may have higher expectations of
quality than older peers, related to less frequent use of health-care
services (Weech-Maldonado et al, 2003; Hubbard et al, 2008;
Lyratzopoulos et al, 2012a) and generational differences in
expectations of autonomy (Benbassat et al, 1998; Gaston and
Mitchell, 2005). Resultantly, younger patients may expect to be
more involved than older peers in decisions about their treatment
and more likely to report negative experience when these higher
expectations are not met. It may also be that younger patients are
treated differently to older patients by care providers, resulting in
variable experiences of care between age groups. Patients in the
oldest age groups (75–84 and 85þ years) also reported more
negative experience than patients in the 65–74-year-old group.
These may reflect communication difficulties experienced by
doctors when engaging with patients of older age related to
declining sensory and cognitive function in these patients. Nearly
half of all cancers occur in patients aged X70 years. It is therefore
important to explore poor experience of decision-making involve-
ment reported by older patients, particularly given concerns about
suboptimal uptake of radical treatments among older patients who
are otherwise fit (Department of Health, 2012).
Ethnic minority patients also reported poorer experience of
involvement in decisions about treatment; a finding concordant
with other studies examining patient experience of care more
generally (Campbell et al, 2001; Weech-Maldonado et al, 2003;
Goldstein et al, 2009; Mead and Roland, 2009; Elliott et al, 2010;
Lyratzopoulos et al, 2012a) and cancer care specifically (Ayanian
et al, 2010). These ethnic inequalities by and large did not reflect
confounding by differences in age, gender, deprivation or cancer
type. Nor were they explained by clustering of ethnic minority
patients in hospitals with below-average patient experience scores;
a finding in contrast to the hypothesis proposed by the English
Department of Health in its analysis of the survey (Department of
Health, 2010a). Service factors potentially responsible for ethnic
disparities of experience have been proposed. Previous reports
suggest an association between access to language and culture-
appropriate services and greater engagement of ethnic minority
patients in care processes (Gordon-Dseagu, 2006). Ethnic
disparities of reported experience of care are greater for older
patients from ethnic minorities than for younger patients
from the same minorities, (Lyratzopoulos et al, 2012a), a finding
consistent with a hypothesis of generational acculturation: younger
generations, raised in the prevailing cultural context of the health
system, are less affected by issues of language or cultural
competence than older generations who are more likely to have
migrated to the country of care as adults. Also, evidence
from other cancer patient surveys suggests that native language
explains some observed variation in patient experience reports
(Ayanian et al, 2010).
The findings identify different groups of patients who are at
greater risk of least positive experience of involvement in decision
making. This profiling can help inform priorities about further
research and improvement efforts. Research and improvement
efforts could explore provision of additional consultation time
with treating clinicians; greater access to cancer specialist
nurses, supporting care professionals or peer support groups; and
additional provision of decision aids and written information
(Friedberg et al, 2013). Some of these improvement efforts
can occur within the same specialty or service environments,
focussing on patients who are likely to require additional
resources or interventions in order to help improve their
experience of shared decision making (e.g., providing additional
decision-making support for patients with multiple myeloma,
within the context of a haematological oncology service, or for
patients with ovarian cancer within the context of gynaecological
cancer services).
Similarly, research and improvement efforts could prioritise
exploring the usefulness of additional support for younger and
ethnic minority patients with cancer. For patients with cancer from
ethnic minority groups, exploring the usefulness of provision of
translational services or translated written material, or interven-
tions that aim to increase the cultural awareness of care providers,
may also be justified.
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The findings also advocate for the need to use case-mix
adjustment of hospital performance of cancer patient experience
measures (O’Malley et al, 2005). This is because using unadjusted
(not case-mix adjusted) hospital scores may inadvertently and
unfairly penalise (or be perceived to unfairly penalise) cancer
centres that specialise in care of patients who face the biggest
challenges in terms of shared decision making, such as ovarian
cancer or myeloma patients, or younger patients with cancer.
Simultaneously reporting both crude and case-mix adjusted
performance may be ideal.
In conclusion, we report large variation in the experience of
involvement in decisions about treatment between patients with 38
different cancers and different sociodemographic characteristics.
Further qualitative research involving patients and clinicians is
justified to generate and test hypotheses regarding causal
mechanisms of observed disparity to help improve care. Addi-
tionally, quantitative research examining potential associations
between disease severity and patient-reported experience is also
needed. In future, better linkage of patient experience and patient-
level clinical data, especially data regarding disease severity and
functional status, would allow for an improved understanding of
how disease state influences patient reports of experience of shared
decision making (and other aspects of care). Furthermore, greater
use of paired report-evaluation questions would allow a better
understanding of the role of differing patient expectations on
observed variation in reported experience (Mead and Roland,
2009). Interventions and improvement initiatives can particularly
focus on patients at higher risk of a less positive experience of
decision-making involvement, such as patients at either extreme of
the age spectrum, ethnic minorities and patients with ovarian,
bladder, myeloma and rectal cancers.
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